What SEC filings does Biomea Fusion, Inc. submit to the SEC?

Biomea Fusion, Inc. (BMEA) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about BMEA?

A Form 4 for BMEA discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Biomea Fusion, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for BMEA?

The 10-K is Biomea Fusion, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all BMEA SEC filings directly on EDGAR?

You can view all historical Biomea Fusion, Inc. filings on the SEC EDGAR company page for BMEA. Each filing card on this page links directly to the original SEC document.

How often does Biomea Fusion, Inc. file with the SEC?

Biomea Fusion, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling BMEA shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

BMEA SEC Filing News — Biomea Fusion, Inc.

Latest SEC filings for Biomea Fusion, Inc. (BMEA) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-14.

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, whic…

Sector: Healthcare Industry: Biotechnology Market Cap: $60.4M

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for BMEA currently lean bullish. Of the 20 displayed SEC filing records, 2 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 8 insider transactions (Form 4) in this period.

BMEA Filing Activity Snapshot 2025-12-04 — 2026-10-14

Insider Transactions (Form 4)

2 buys vs 0 sells

Net insider buying in this period — more purchases than sales reported.

Largest Form 144 Filing

$99.2K

Hitchcock Michael J.M. (Director, Interim CEO) · 2025-12-04

100,000 shares · Form 4

Insider Transactions 8 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 8 filings in this group are Form 4s for Biomea Fusion, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 8 insider filings shown, the breakdown is 6 compensation award and 2 open-market purchase. 2 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×6: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market purchase ×2: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Form 4 Compensation award Tax / Compensation Filing 2026-06-12

BMEA insider Form 4 filed for equity award, exercise, or tax withholding

Faust Elizabeth (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	196,299	—	—

Filing: Form 4 (Insider Transaction) Insider: Faust Elizabeth (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-12

BMEA insider Form 4 filed for equity award, exercise, or tax withholding

AGUIAR ERIC (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	196,299	—	—

Filing: Form 4 (Insider Transaction) Insider: AGUIAR ERIC (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-12

BMEA insider Form 4 filed for equity award, exercise, or tax withholding

Ray Sumita (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	196,299	—	—

Filing: Form 4 (Insider Transaction) Insider: Ray Sumita (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-12

BMEA insider Form 4 filed for equity award, exercise, or tax withholding

Averill Julianne (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	173,711	—	—

Filing: Form 4 (Insider Transaction) Insider: Averill Julianne (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-04-03

BMEA insider Form 4 filed for equity award, exercise, or tax withholding

Erdtmann Rainer M (Director, See Remarks) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	452,512	—	—

Filing: Form 4 (Insider Transaction) Insider: Erdtmann Rainer M (Director, See Remarks)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-04-03

BMEA insider Form 4 filed for equity award, exercise, or tax withholding

Hitchcock Michael J.M. (Director, Interim CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	667,477	—	—

Filing: Form 4 (Insider Transaction) Insider: Hitchcock Michael J.M. (Director, Interim CEO)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2025-12-15

BMEA insider Erdtmann Rainer M (Director, See Remarks) bought 30,000 shares (~$43.0K)

Erdtmann Rainer M, listed as Director, See Remarks at Biomea Fusion, Inc., reported an open-market purchase of 30,000 BMEA shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	30,000	$1.43	$43.0K

Filing: Form 4 (Insider Transaction) Insider: Erdtmann Rainer M (Director, See Remarks) Shares: 30,000 Est. Value: $43.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2025-12-04

BMEA insider Hitchcock Michael J.M. (Director, Interim CEO) bought 100,000 shares (~$99.2K)

Hitchcock Michael J.M., listed as Director, Interim CEO at Biomea Fusion, Inc., reported an open-market purchase of 100,000 BMEA shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	100,000	$0.99	$99.2K

Filing: Form 4 (Insider Transaction) Insider: Hitchcock Michael J.M. (Director, Interim CEO) Shares: 100,000 Est. Value: $99.2K

View on SEC EDGAR → Open Filing Document →

Material Events 9 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 9 in this period for Biomea Fusion, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-14